EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab

Henrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, Bjørn Henning Grønberg, Tarje Onsøien Halvorsen, Maria Moksnes Bjaanæs, Britina Kjuul Danielsen, Mari Børve, Solveig Kokkvoll, Tonje Sofie Dalen Boda, Åsa Kristina Öjlert, Åslaug Helland

Journal of Thoracic Oncology · 2026

DOI: 10.1016/j.jtho.2026.103992 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Thoracic Oncology, 2026. Verfasst von Henrik Horndalsveen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospita…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, South-Eastern Norway Regional Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The benefit of durvalumab after chemoradiotherapy (CRT) varies widely in unresectable stage III NSCLC. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection may help identify patients at high risk of early treatment failure during and after durvalumab. METHODS: In this prospective multicenter study, patients with unresectable stage III NSCLC received CRT followed by durvalumab. Plasma samples were collected at screening, after CRT, at predefined time points during durvalumab, and during post-treatment follow-up. A tumor-agnostic, hybrid-capture ctDNA MRD assay personalized to each patient classified samples as ctDNA detected (MRD positive) or not detected (MRD negative). RESULTS: A total of 659 plasma samples from 84 patients were analyzed. Detectable ctDNA before the seventh cycle of durvalumab (after 6 mo of treatment) and 3 months after treatment completion was strongly associated with inferior progression-free survival (PFS) (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.18-5.11, p = 0.013 and HR: 5.37, 95% CI: 1.93-14.93, p < 0.001, respectively). Detection of ctDNA after CRT but before durvalumab initiation was not prognostic (HR: 1.38, 95% CI: 0.78-2.41, p = 0.269). In a multivariable time-dependent Cox model incorporating all post-CRT samples, detectable ctDNA was associated with a nearly threefold higher risk of progression (HR: 2.95, 95% CI: 1.69-5.15, p < 0.001). CONCLUSIONS: Detectable ctDNA during and after durvalumab was associated with markedly shorter PFS in unresectable stage III NSCLC. Serial ctDNA-based MRD assessment may help identify patients at high risk of relapse who could benefit from alternative or intensified treatment strategies, ideally within prospective clinical trials. GOV IDENTIFIER: NCT04392505.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungChemoradiotherapyCirculating Tumor DNALung NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm StagingNeoplasm, ResidualProspective Studies

Stichwörter der Autor:innen

ChemoradiotherapyCirculating tumor DNAImmunotherapyLocally advanced NSCLCMinimal residual disease

Substanzen

Antibodies, MonoclonalCirculating Tumor DNAdurvalumab

Autor:innen und Institutionen

  • Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Clinical Medicine, University of Oslo,…
  • Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Department of Pulmonology, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Förderung

  • AstraZeneca
  • South-Eastern Norway Regional Health Authority

Zitieren

APA

Horndalsveen, H., Haakensen, V. D., Madebo, T., Grønberg, B. H., Halvorsen, T. O., Bjaanæs, M. M., Danielsen, B. K., Børve, M., Kokkvoll, S., Boda, T. S. D., Öjlert, Å. K., & Helland, Å. (2026). ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2026.103992

Vancouver

Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Bjaanæs MM, et al. ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. Journal of Thoracic Oncology. 2026. doi:10.1016/j.jtho.2026.103992

BibTeX
@article{Horndalsveen2026,
  author = {Horndalsveen, Henrik and Haakensen, Vilde Drageset and Madebo, Tesfaye and Grønberg, Bjørn Henning and Halvorsen, Tarje Onsøien and Bjaanæs, Maria Moksnes and Danielsen, Britina Kjuul and Børve, Mari and Kokkvoll, Solveig and Boda, Tonje Sofie Dalen and Öjlert, Åsa Kristina and Helland, Åslaug},
  title = {ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab},
  journal = {Journal of Thoracic Oncology},
  year = {2026},
  doi = {10.1016/j.jtho.2026.103992}
}
Kostenlos starten →